Anaesthetic management of coronary artery bypass grafting in a patient with central core disease and susceptibility to malignant hyperthermia on statin therapy.
Central core disease and malignant hyperthermia (MH) are both associated with mutations in the RYR1 gene. We report the anaesthetic management of one such patient presenting for coronary artery bypass grafting. Her medication included aspirin 75 mg, atorvastatin 20 mg, isosorbide mononitrate 60 mg, atenolol 25 mg and glyceryl trinitrite sublingual spray as required. The use of aprotinin, statins and moderate hypothermia in patients with central core disease and known susceptibility to MH has not been documented.
Johi
R R
RR
Department of Anaesthesia, William Harvey Hospital, Kennington Road, Ashford, Kent TN23 3AQ, UK. rrjohi@aol.com
Mills
R
R
Halsall
P J
PJ
Hopkins
P M
PM
D000328:Adult; D000771:Anesthesia, Intravenous / Q000379:methods*; D000924:Anticholesteremic Agents / Q000009:adverse effects; D007611:Aprotinin / Q000009:adverse effects; D000069059:Atorvastatin; D001026:Coronary Artery Bypass; D005260:Female; D006538:Heptanoic Acids / Q000009:adverse effects; D006801:Humans; D008305:Malignant Hyperthermia / Q000150:complications*; D020512:Myopathy, Central Core / Q000150:complications*; D011758:Pyrroles / Q000009:adverse effects
D000924:Anticholesteremic Agents; D006538:Heptanoic Acids; D011758:Pyrroles; D007611:Aprotinin; D000069059:Atorvastatin